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Abstract
Ovarian cancer is a dismal disease, affecting thousands of women in the US
alone, with a five year survival rate of only 45.6%. Standard of care for ovarian cancer
typically includes surgery and chemotherapy, which often only prolongs the struggle
against the disease rather than end it. Platinumbased chemotherapeutics are generally
effective against ovarian tumors for a time, but the cancer usually relapses with a
resistance to platinum. Targeted therapeutics have proven effective in treating other
tumor types as part of a multidrug treatment. Such drugs, celecoxib, sorafenib, and
sildenafil, were used in combination to activate or inhibit relevant kinase cascades,
cellular efflux pumps, and chaperone proteins which caused established and newly
isolated ovarian cancer cells to undergo apoptosis and necrosis. Additionally, the drug
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combination was able to resensitize resistant ovarian cancer cells to the platinum drugs
through an unknown mechanism.

Introduction
Ovarian Cancer
In the United States alone, approximately 22,000 women will be diagnosed with
some form of ovarian cancer in 2015. Of those already diagnosed, 14,180 are expected
86
to die from the disease this year.
While the prevalence of ovarian cancer is relatively

rare, accounting for only 1.3% of all new cases, and 2.4% of all cancer deaths, current
86
research in this area is severely underdeveloped.
Total funding for ovarian cancer

research from the National Cancer Institute was $100.6 million, or 2.1% of the total NCI
67
budget, in 2013.
Compared to the $559.2 million spent on breast cancer research, the
67
current allocation for ovarian cancer seems dismally anemic.
When considering that,

by a matter of physiology, only women are atrisk for developing ovarian cancer, the
relatively low prevalence does not seem entirely relevant. Considering the fiveyear
survival rate is therefore a better point of reference for the understanding of the ferocity
of ovarian cancer.
Fiveyear survival rates are a standard reference point in explaining the
21,36,19
aggressiveness and mortality rate of any given cancer type.
This convention

began within the medical field in the 1930s when surviving past the initial, palpable
36
onset of disease was the major hurdle associated with cancer treatment.
In the 1970s,

the NCI adopted this metric for describing different cancer types, which solidified the
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36
fiveyear survival rate as a standard within the fields of cancer research and treatment.

Between the years of 2005 and 2011, the average fiveyear survival rate of all women
86,19,80
diagnosed with any stage of ovarian cancer was 45.6%.
The individual story, like

with any given cancer, changes drastically based on when the disease is diagnosed,
and which type of cells within the organ are affected. For instance, women diagnosed
with Stage I germ cell tumors of the ovary have a 98% chance of reaching the five year
posttreatment mark, whereas women diagnosed with Stage IV invasive epithelial
21,19
ovarian cancer have only a 17% rate of five year survival.
Currently, the best

biomarker for diagnosis of epithelial ovarian cancer is Cancer Antigen 125,
79,18,49,66 
(CA125).
Within the ovarian cancer community, CA125 is known to be a fairly
79,49
poor biomarker as it lacks in both specificity and sensitivity.
Unfortunately, due to a

lack of early detection methods, and seemingly ambiguous initial symptoms, only about
20% of all ovarian cancers are found at an early stage, resulting in the overall dismal
20,19,68,79,18
prognosis.
Moreover, the types of ovarian cancers diagnosed early are

typically from biological origins which are less virulent than those of the tumor types
79,18
which are diagnosed at later stages.
All told, ovarian cancer is the most lethal type of
79,18
gynecologic malignancies in developed countries.

Table 1 provides the names and characteristics of the ovarian cancer lines used
throughout this study.
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Cell Line

Cell Type

Characteristics 5,6,19,68,8,35,117


OVCAR3

Epithelial

Resistant to cisplatin

SKOV3

Ascites

Cisplatin resistant. p53 gene
deletion

CAOV3

Epithelial

Overexpresses mutant p53

CAOV4

Epithelial

Lossoffunction in p53 gene,
sensitive to cisplatin

PA1

Metastatic site
ascites

NRas activated

Spiky

PDX

Intrinsic resistance to cisplatin and
taxane

MCVH OP1

PDX

Unknown

CTG1677 #1 and
CTG1677 #2

PDX

Unknown

CTG1703 #1 and
CTG1703 #2

PDX

Unknown

Table 1.
Ovarian cancer cell lines used in this study along with their location of
origin and characteristics.

Standard of Care
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The care administered to any given woman will vary significantly depending on
the aggressiveness and accessibility of the woman’s cancer. While the first course of
action for most cases will be a debulking surgery in which the goal is to remove as
much of the cancerous tissue as possible, some women (with Stage III or Stage IV (2))
106,110,22,64,97
are given neoadjuvant chemotherapy prior to debulking.
Women considered

good candidates for the surgical laparotomy benefit from a physical reduction in the
amount of cancerous tissue as well as a more accurate diagnosis and staging, which
106,110,64,97
will educate the medical team on which course of treatment is best indicated.

The relative invasiveness of the surgery depends largely on the perceived progression
of the disease. It is possible, though not common, and only for germ cell tumors, to
remove only part of one ovary, or simply the reproductive structures on the affected side
106,22,64,33
of the parallel system in order to preserve the fertility of the woman.
In a very

limited number of women, this relatively simple surgery suffices for their entire
22,33
treatment.
Often, the cancer is bilateral, and both ovaries must be completely or
22,64,33
partially removed.
The aggressiveness of the surgical plan, and how much tissue

will be removed, depends largely on the perceived invasiveness of the cancer, and the
106,22,64
woman’s desire to bear children.

After the initial surgery, women with ovarian cancer will undergo three to six
cycles of a combinational drug chemotherapy regimen which, notably, typically includes
platinumbased alkylatinglike agents like cisplatin (CIS), carboplatin (CARBO), or
23,110.64,22,33
oxaliplatin (OX).
CARBO is the most commonly prescribed medication, with

CIS being the second most, and OX used rarely for the treatment of ovarian cancer. In
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germ cell ovarian carcinomas, the common combination is cisplatin, etoposide, and
22,23,67,11
bleomycin, known as PEB.
The standard of care for epithelial ovarian cancer,
62,107
which is the lineage of interest to this study, is CARBO with a taxane.
The

debulking phase of treatment enables penetration of the drugs into the active tumor
23,64,22,33
cells so as to maximize effectiveness of the chemotherapeutics.
Much of the
62,107
benefit of a debulking procedure is in the removal of resistant clones.
In clinical

terms, “optimal debulking” is achieved when the residual tumor has a volume of less
than 1 cm, with “suboptimal debulking” encompassing all tumors larger than 1 cm.
Delivery mechanisms for the chemotherapeutics vary depending on the stage and
precise location of the cancerous cells as well as the debulking status. Both intravenous
and intraperitoneal routes can be taken, and are decided upon based on the individual
case with which the healthcare team is confronted, with intraperitoneal being the route
23,64
of choice for the more aggressive and advanced tumors.
For instance,

intraperitoneal injections are reserved for optimally debulked tumors. Radiation therapy
is not currently utilized for ovarian cancer due to the risk of damaging otherwise healthy
abdominal organs, and the typical spread of the disease is already outside the compact
64,22.33,17,52
range of radiotherapy death.

The bleak prognosis for many women with an ovarian cancer diagnosis is due to
17,18,22,20,60,23
recurrence of disease rather than the initial onset.
Maintenance therapy is

used to keep the aberrant cell growth at bay, but this does little to eradicate the
33,17,22
cancer.
Many of these tumors display a resistance to the firstline

chemotherapeutics, specifically the platinumbased drugs; there is a high mortality rate
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33,17,22,20,18,23,102,60,48
associated with recurrence.
As platinumbased drugs damage DNA,

leading to apoptosis, the resistance to such drugs appears to be rooted in the selection
of cells with more effective survival pathways against platinumbased therapeutics by
23,47,112,27,38
virtue of their upregulating survival and downregulating apoptotic signals.

Targeted Therapy
Conventional chemotherapy does not distinguish cancer cells from healthy cells.
Acting cytotoxically, and distributed systemically, traditional chemotherapeutics kill all
cells which are rapidly dividing. Not only does this lack of specificity to cancer cells
cause the side effects most closely associated with chemotherapy, but the general
3
cytotoxic effects limit the scope of impact on the tumor.
Patients typically experience

only brief and incomplete tumor reduction from treatment with conventional
3,49
chemotherapeutics.
Targeted therapy is a relatively new approach to chemotherapy
3,10 
which may address these issues inherent in conventional chemotherapy.
Instead of

interfering with the cellular machinery which is common to all actively dividing cells,
targeted therapy is an attempt to exclusively inhibit cancer growth via interaction with
markers specific to the cancerous tissue which are not present, or not active, in the
3,10
healthy tissue.
Ideally, targeted chemotherapy kills cancer cells selectively, allowing

for specific tumor death without the deleterious effects on the patient’s normal
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3,10
systems.
However, cancer cells are categorically adept at developing and utilizing

crosstalking survival pathways in an attempt at continued growth and proliferation.
Therefore, it is unlikely a single drug therapy will eradicate the disease from a given
patient, but will instead lead to developed resistance to the drug. Combinational
targeted drug therapy may very well be the answer to the problem of conventional
chemotherapy toxicity and targeted drug resistance.
Targeted therapy comes in multiple forms. Some of the more recently used
therapeutic interventions are monoclonal antibodies designed to harness the patient’s
49
immune system to attack the cancer.
Similarly, immunotoxins are another type of

targeted therapy which selectively bind to specific cancer markers using an antibody
49,71
fragment.
Instead of using leukocytes to kill the mutated cells, immunotoxins release

a cytotoxic substance into the cell once endocytosed to effectively, yet exclusively, kill
49,71
49
cancer.
Finally, many targeted therapies are small molecule inhibitors.
The

structure of these drugs mimic that of endogenous molecules, allowing them to bind to
active sites of proteins such as receptors or enzymes to limit or completely inhibit their
function, and so disrupt aberrantly activated intercellular pathways involved in cell
3,49 
survival, potentially leading to cell death..
The targeted therapies used in this study

are all small molecule inhibitors, and are individually detailed below.
Unfortunately, ovarian cancer does not have any druggable targets which are
exceptional in relation to other cancers. Thus, the targeted therapies used in this study
were chosen as they interfere with prosurvival pathways generally rather than any
specific ovarian cancer survival mechanism.
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Platinum Drugs
Almost forty years after receiving FDA approval, the use of platinumbased
chemotherapeutics is still standard for treating several tumor types such as testes,
74,23,111,47
head, neck, cervical, nonsmallcell lung, and ovarian.
Like many drugs, the

discovery of the effects of platinum compounds on cell division was entirely
74,83
accidental.
During an experiment concerning 
Eschireichia coli
and electricity,
74,83
platinum electrodes were used as they were assumed to be inert.
After noticing the

bacteria were growing to extraordinary lengths, the research team concluded that the
platinum electrode had interacted with the solution to produce the compound now
74,47,82
known as cisplatin.
Without being entirely clear on the mechanism of action, the

team understood the potential implications of this compound in human diseases such as
cancer. Today, despite being commonly used to treat various cancers, exactly how
cisplatin and other platinumbased drugs actually inhibit cell growth and cause
23,111
apoptosis is not entirely explained.

What is known is that platinumbased drugs interact with DNA. Cisplatin is a
neutral, inorganic, square planar molecule which must undergo several spontaneous
23,32
aquation reactions to become primed as a reactive species.
Once activated, cisplatin

can then interact with purine bases in DNA resulting in DNAprotein and DNADNA
adducts both interstrand and intrastrand, with the intrastrand being the most detrimental
23,111,103
to cell division.
Unless the cell is able to repair the damage caused by the
23,111
cisplatin, the cell will eventually enter apoptosis.
The three platinum drugs used in
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this study are cisplatin, the original, as well as the newer carboplatin and oxaliplatin
which are better tolerated by patients. Both of the newer drugs are thought to have
mechanisms of action similar to that of cisplatin with perhaps carboplatin also releasing
2+
cytoxic Pt
in vitro.29

Structures of all three drugs are below.

88
Figure 1. Chemical structure of cisplatin

94
Figure 2. Chemical structure of carboplatin

97
Figure 3. Chemical structure of oxaliplatin
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Platinum Resistance
Platinum therapeutics are often effective for a time, but gradually lose their ability
to remain lethal to a given tumor after a short period. Even within ovarian cancer,
platinum drugs illicit an initial response of tumor reduction in up to 70% of women, but,
93,70
as the survival rate shows, quickly become fairly ineffective in those same women.

Interestingly, tumors which become platinum resistant often develop resistance to
93,70
completely unrelated antitumor drugs.

Without anyone knowing precisely how platinums work to kill cancer cells, it is
difficult to pinpoint why they lose their effectiveness or how resistance develops. The
working model for how tumors become platinum resistant involves intracellular drug
reduction, accumulation of intracellular thiols, and upregulation of multiple antiapoptotic
93,111,70,46
pathways.
Intracellular drug levels become reduced in many cell lines after

exposure to platinum drugs, and have been diminished by as much as 90% compared
93,46
to initial concentrations.
Both efflux and influx are implicated in this form of
93,46
resistance, with perhaps influx being the major culprit.
With lingering uncertainty as

to how exactly the drugs are taken into the cell, or how large a part drug efflux plays in
resistance, it is difficult to simply up or downregulate cellular pumps as a means of
93,46
reversing resistance.

Another mechanism of cisplatin, and all platinum, resistance is linked to
93,77
increased glutathione concentrations in several cisplatinresistant tumor models.

Much in the same way as cisplatin itself forms adducts within DNA, GSH binds with
93,77
cisplatin leading to the drug’s inactivation.
GSHbound cisplatin cannot then go on to
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bind to DNA, so the relative increase of GSH as cells are treated with platinums
93.77
diminishes any response the patient has to further platinum treatment.
Ironically,the

high reactivity aquated cisplatin utilizes to fight cancer cells enzymatic independently is
exactly the same property GSH utilizes to undercut cisplatin. Of course, GSH is a potent
93,77,46
endogenous antioxidant.
As such, the increased levels of GSH in platinum treated

tumors probably lead to cell survival by aiding in DNA repair and buffering oxidative
stress, both of which actions prevent apoptosis, as well as through direct inhibition of
93,77,46
cisplatin.

Cancer cells by definition have altered survival and apoptotic protein expression
and function. The prosurvival and antiapoptotic pathways are exacerbated even more in
93,46
platinum resistant tumor lines.
With copious crosstalk between pathways, cancer

cells ward off platinumdrug induced apoptosis through upregulating phosphoinositide
3kinase (PI3K) and protein kinase B (AKT) activity, deregulating the mitogen activated
protein kinase (MAPK) pathway, increasing the cell’s tolerance to DNA damage,
suppressing caspase activity, increasing Bcl2/xL, downregulating Bcl2associated X
protein (Bax) or Bcl2associated death promoter (Bad), and overexpressing Harvey rat
93
sarcoma viral oncogene homolog (HRAS).
The culmination of this effort at survival

vastly overwhelms the therapeutic effect of the platinum drugs, and the patient’s tumor
ceases to respond.
The aim of the current study was to restore and retain the cytotoxicity of platinum
drugs in ovarian cancer cells. This study utilized combinational targeted drug therapy to
directly interfere with these resistance mechanisms.
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Sorafenib
Sorafenib (also known as BAY 439006 or Nexavar) is a multikinase inhibitor
which, after only 11 years of development, was FDA approved in 2005 for oral
115,46,97
administration in the treatment of renal cell carcinoma.
Further use has shown the

drug has broad inhibitory effects on wildtype and mutant rapidly accelerated
fibrosarcoma (Raf) kinase and several tyrosine kinase receptors, to include rearranged
during transfection (Ret),Mast/stem cell growth factor receptor (cKit), vascular
endothelial growth factor receptor (VEGFR), plateletderived growth factor receptorbeta
78,1,79,90,92,55,114,115,53,39,96,61
(PDGFRβ), and Fmslike tyrosine kinase 3 (FLT3) (Figure 8).

Crystallography has shown that sorafenib works, in part, by binding to the ATPbinding
81
pocket of Raf which inhibits substrate binding and phosphorylation (Figure 8).
Despite

the number of kinases sorafenib inhibits, the drug remains a form of a targeted therapy
as it retains a level of specificity, not binding to protein kinases like mitogenactivated
81
protein kinase kinase (MEK) or extracellular signalregulated kinase (ERK).
By

blocking the action of several tyrosine kinase receptors, and Raf, sorafenib has been
shown to be antiproliferative, antiangiogenic, and antisurvival both 
in vitro
and 
in
vivo
.78,1,79,114,115,53,96

The Dent lab has previously shown sorafenib (sor) also acts to induce
78,79
endoplasmic reticulum stress (ER stress) in human leukemia cells.
Cells treated with

sorafenib contained higher than baseline levels of reactive oxygen species, decreased
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levels of the chaperone protein GRP78, and reduced levels of the antiapoptotic protein,
78,79
myeloid cell leukemia 1 (Mcl1).
90,92,53,61,46
Sorafenib is typically given in 400 mg doses twice daily in the clinic.

Clinical trials using sorafenib have had mixed results. Patients who received the
clinically relevant doses at times enjoyed only modest results, but often experienced
53,39,61
symptoms of rash, diarrhea, edema, and handfoot syndrome.
However, other

studies have shown positive results from clinical trials with tumors responding well with
90,92,115,96
easily tolerated side effects.
Adverse side effects of sorafenib may be mitigated
46
by temporarily reducing the dosage of the drug, or interrupting treatment briefly.

Interestingly, the more responsive tumors were often later stage, and the sorafenib was
90,92,115,96
given in combination with other drugs.

Sorafenib was used in this study for its inhibition of multiple tyrosine kinases and
Raf, as well as for its demonstrated proapoptotic qualities via ER stress. Sorafenib is
currently used in the clinic, and is soon to be generic, so accessibility of the drug also is
a motivating factor for testing its effectiveness in killing ovarian cancer as well as
resensitizing the cancer to platinum therapeutics.
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114
Figure 4. Chemical structure of sorafenib

Sildenafil
Sildenafil (also known as Revatio or Viagra) is an oral phosphodiesterase type 5
(PDE5) inhibitor, which has proven to have broader applications than originally
anticipated. Formulaically intended to aide in the treatment of angina pectoris, sildenafil
12
was found to have limited cardiovascular effects.
Instead, the drug was noted to have

profound effects as a novel therapeutic for the treatment of erectile dysfunction,
eventually receiving approval from the FDA as such in 1998. The drug acts by inhibiting
PDE5, the enzyme responsible for breaking down cyclic guanosine monophosphate
12,116,43,84
(cGMP) within cells.
Sildenafil (SIL) is able to selectively inhibit PDE5 due to the

drug’s structural similarity of the drug to cGMP, thus binding in the active site of PDE5
116,12
and blocking the enzyme’s degradative activity (Figure 6).
With an inhibited PDE5,

the cell accumulates nitric oxide (NO) and cGMP, which activates protein kinase G
12,116,43,84
(PKG), and, in turn, decreases the calcium concentration within the cell.
This
12,116,43,84
mechanism leads to smooth muscle relaxation, thus, penile erection.
Sildenafil
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is typically welltolerated, and taken orally at 50mg or 100mg doses for the treatment of
57
erectile dysfunction.

Given that sildenafil was originally formulated for a purpose other than the one
for which it received FDA approval, it is ironic that the drug has proven to be an effective
therapeutic or preventative agent for a variety of cardiac conditions and other diseases
26,43,84
with common comorbidities of erectile dysfunction.
In the context of this study,
104,14,59,68,16,15
sildenafil is used for its demonstrated anticancer properties.

Many studies, including others produced in the Dent lab, have used sildenafil to
complement combinational therapy regimens against various tumor
104,14,59,68,16,15,100 
types.
Often, PDE5 is overexpressed in many tumors, so the selective
104,14
inhibition of such is a relatively safe, direct, and effective mode of therapy.
Other

studies have noted that abnormally raised cellular concentrations of cGMP activate the
mitogenactivated protein kinase kinase kinase 1 (MEKK1)/ mitogenactivated protein
kinase kinase (MKK)/ Jun Nterminal kinase (JNK) pathway, resulting in apoptosis
105,99,34
105
(Figure 6).
PKG itself can trigger apoptosis through caspase activation.
In

addition to mechanistically increasing cellular cGMP levels, and activating proteins
thereby, sildenafil has been credited with aiding to cause ER stress, eventually forcing
cancer cells into apoptosis, by directly increasing the amount of ROS, and with reducing
resistance to medications by blocking the cellular efflux pumps ABCB1 and
104,14,59,68,16,15,91,105
ABCG2.

Finally, it is worth noting that lowdose sildenafil in the form of Revatio is currently
offpatent, and higher dose sildenafil in the form of Viagra will be generic within the next
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five years. While doing nothing mechanistically for the therapy, logistically the therapy
proposed in this study is more realistic given an affordable drug combination.
For these reasons, sildenafil was chosen as one of the targeted therapies in the
combination.

116
Figure 5. Chemical structure of sildenafil
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Figure 6. Diagrammatic representation of sildenafil’s mechanism of action,
105,99,34 
including proposed cancer therapeutic pathway.
Sildenafil potentially acts
through three mechanisms as an anticancer drug. Sildenafil blocks drug efflux through
inhibition of cellular pumps ABCB1 and ABCG2. Sildenafil directly increases the
oxidative stress of the cell through generation of reactive oxygen species, which can
lead to apoptosis. Sildenafil blocks PDE5 degradative activity of cGMP. This leads to an
increased concentration of cGMP which can either activate PKR or the
MEKK1/MKK/JNK pathway and trigger apoptosis.

Celecoxib
Celecoxib (also known as Celebrex) is a nonsteroidal antiinflammatory drug
(NSAID) pain reliever which was introduced in the United States in 1999 for the
treatment of rheumatoid arthritis and osteoarthritis by selectively blocking
73,28
cyclooxygenase2 (COX2).
While other NSAIDs are nonselective, thus interfering

with the intestinally protective COX1, celecoxib reduces pain and inflammation without
28,109,73
causing gastrointestinal distress.
The cyclooxygenase family of enzymes is

responsible for converting arachidonic acid into prostaglandins, thus the inhibition of the
enzymes results in the reduction of prostaglandins and pain relief (Figure 8). The drug
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has comparable efficacy to ibuprofen as an analgesic, and is typically administered
28
orally in 200mg or 400mg doses.

In the time since FDA approval, celecoxib (cel) has proven to have therapeutic
effects beyond pain relief. While the direct mechanism is unclear, COX2 is implicated in
multiple conditions such as Alzheimer's disease, depression, premature labor, and
54,98,109,65,41
cancer.
Celecoxib has been shown to alleviate or slow the progression of
54,98,109,4,65
these conditions.
With regards to this study, cancer is a disease of chronic

inflammation. Celecoxib’s inhibition of inflammatory prostaglandins may be the source
of the drug’s anticancer properties as prostaglandins stimulate prosurvival pathways in
a paracrine and autocrine fashion once secreted from the original cell (Figure
15,28,54,98,109,65,73,41
8).
Reportedly, the drug acts to inhibit activation of prosurvival protein,

AKT, by preventing PI3K from activating phosphoinositidedependent kinase 1/2
110,109
(PDK1/2) (Figure 8).
Blocking the actions of AKT would facilitate forcing cells into

apoptosis.
An alternative explanation for celecoxib’s effectiveness against cancer pertains to
4
the cellcell adhesion protein, Cadherin11.
Several tumor types have upregulated

cadherin11 expression, and some seem dependent on the protein for continued
4
progression.
Celecoxib has been shown to bind to cadherin11, thus disabling the
4
protein.

Regardless of the precise mechanism, celecoxib is regularly demonstrated, by
the Dent lab and several others, to be an effective targeted therapy against cancer as
15,28,54,98,109,4,73,41
both a single agent, and in combination with other targeted therapies.
A
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recent report has even used celecoxib in combination with sorafenib, as this study does,
and showed synergistic effects on hepatic carcinomas 
in vitro
.63

Of practical note, celecoxib is now available generically, which reduces the
patient’s burden of cost for the treatment. For this, and the reasons above, celecoxib
was chosen for the combinational therapy in this study.

41
Figure 7. Chemical structure of celecoxib
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Figure 8. Diagrammatic representation of sorafenib and celecoxib’s mechanisms
97,110,63,85,56,117,58 
of action.
Sorafenib inhibits tyrosine kinase receptors as well as the
Raf/MEK/ERK survival pathway. Celecoxib inhibits the conversion of arachidonic acid
conversion to PGE2 by blocking the action of COX2. Celecoxib also inhibits
PI3Kmediated activation of PDK1/2, blocking activation of AKT.

MitogenActivated Protein Kinase (MAPK) Pathways
The MAPK pathways are a family of highly conserved, tiered signaling cascades
responsible for the transmission and amplification of extracellular stimuli to the nucleus

30

72,87,24,82,75
of a given cell.
The hallmark of these cascades is the threetiered system

comprised of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK),
75
and a MAP kinase (MAPK).
The three tiers are in series with one another, and each

downstream kinase is activated by phosphorylation from its upstream kinase kinase
72,24
(Figure 9).
The cascade is activated when an extracellular signal binds to its
72,87,24
appropriate receptor on the plasma membrane.
The signal is then transduced,

transmitted, and amplified as it travels down the phosphorylation cascade to the nucleus
of the cell where it activates effector proteins responsible for a diverse set of cellular
75,72,24
responses to include differentiation, proliferation, and death (Figure 9).

The four typically accepted, major MAPK pathways are the extracellular
signalregulated kinases (ERK1 and ERK2), p38 kinase isozymes (p38α, p38β, p38y,
75,72,37
and p38δ), Jun Nterminal kinase (JNK1, JNK2, and JNK3), and ERK5 (Figure 9).

Importantly, each MAPK pathway has the ability for crosstalk with other MAPK
pathways within the cellular signalling network for the sake of regulation and resolution
37
of opposing cellular cues.
They are not totally isolated systems. In normal,
72,37
differentiated cells, regulation of the MAPK network is wellbalanced and regulated.

However, cancer cells often have one or several deregulated MAPK pathways, allowing
for the cell’s propensity for growth and proliferation rather than stasis or
72,37,30,31,97
apoptosis.
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72,75,37
Figure 9. Diagrammatic representation of the four major MAPK pathways
MAPK pathways are signalling cascades comprised of threetiers of kinases in which
the upstream MAPKKK phosphorylates the appropriate MAPKK, which phosphorylates
the appropriate MAPK, which results in a cellular response specific to the original signal.
Both the p38 and JNK1/2/3 pathways can respond to a radiation, stress, and
inflammation. The ERK1/2 pathway responds to growth factors. The ERK5 pathway
responds to stress.
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Unfolded Protein Response
In eukaryotic cells, the ER is responsible for the folding and assembly of proteins
101,42
to be passed on to other cellular compartments or secreted extracellularly.
Proteins

which have been folded properly are transported out of the ER, while those which are in
42
some way defective are sequestered for remedial processing.
Such defections can

occur through mutation, hypoxia, infection, improper and, like in cancer, high metabolic
42,101 
demand.
Due to the inherent inefficiency of cancer cells, the ER often becomes
101 
saturated with misfolded and unfolded proteins.
The accumulation of defective

proteins triggers the unfolded protein response (UPR) in an attempt to
restore
101,89,51
homeostasis and ease the ER stress.
The innate metabolic weakness of cancer

makes exacerbating the UPR, and forcing the cell into apoptosis, an obvious goal of
targeted therapies. Initiation of the UPR is characterized by the activation of PKRlike
endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6), and
inositol requiring enzyme 1 (IRE1) following their dissociation from glucoseregulated
101,42,69,113
protein 78 (GRP78(BiP)).

Chaperone proteins, like GRP78, are evolutionarily conserved polypeptides
13,76
essential to the normal functioning of the ER.
These chaperones are tasked with

binding to misfolded proteins and altering their structure to a normal, functioning
13,76
configuration.
A relative increase in the abundance of unfolded proteins within the

lumen of the ER causes GRP78 to decouple from ER membranebound PERK, ATF6,
101,42,69,113,13
and IRE1 (Figure 10).
The active GRP78 then attaches to the misfolded

protein and works to correct the deficient structures before their overabundance triggers
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13
apoptosis.
Apoptosis, of course, is an evolutionarilyconserved controlled death

mechanism by which the cell enters a programmed form cell death, through DNA
101,51,69,42,13
fragmentation, cell shrinkage, membrane blebbing.

While GRP78 attempts to resolve the ER stress, PERK, ATF6, and IRE1 each
51,113,50
trigger a cascade to cope with the cellular crises.
Activated PERK phosphorylates

eIF2α which then both halts bulk protein synthesis, so as to prevent additional backlog
51,69,42,113 
of unfolded proteins, and activates transcription factor ATF4 (Figure 10).
In turn,

ATF4 leads to the translation of additional proteins to alleviate the ER stress, or C/EBP
101,51,44,113 
homologous protein (CHOP).
If the ER stress is not alleviated, CHOP

downregulates the antiapoptotic BCL2 and triggers programmed cell death,
101,51,44,113
apoptosis.
Meanwhile, the active ATF6 and IRE1 activate simultaneous
113,101, 89 
cascades to cope with the stress (Figure 10).
Both ATF6 and IRE1 activity

cause an increase in the folding capacity of the ER, through an increase in chaperones
such as GRP78, and in the activity of endoplasmicreticulumassociated protein
degradation (ERAD), a process through which misfolded proteins are degraded outright
51,69,42,113,55 
rather than refolded.
Both of the previous are prosurvival adaptive pathways.

Additionally, the IRE1 cascade has the ability to promote apoptosis through RNA decay
113,69
and JNK activation.

Apoptosis and the UPR were examined in this study as they are implicated as
mechanisms of action for the drug combination’s toxic effects.
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89,44,113 
Figure 10. Diagrammatic representation of the basic UPR pathway
In
response to unfolded proteins, BiP ( also referred to as GRP78) dissociates from PERK,
ATF6, and IRE1, respectively, to refold the protein. The membranebound PERK, ATF6,
and IRE1 become activated following dissociation from BiP. Active IRE1 triggers
signaling which results in RNA decay and JNK activation to promote apoptosis.
Concurrently, IRE1, and ATF6, upregulate transcription factors which result in an
increase in chaperone proteins, ERAD, and the size of the ER. Concurrently, PERK
activation causes phosphorylation of eIF2α which both halts bulk protein translation, and
activated ATF4. Activated ATF4 translocates to the nucleus to activate transcription
factor CHOP, which results in suppression of the BCL2 family, and an overall
promotion of apoptosis.
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Materials and Methods
Materials
All drugs used in the the course of this study (to include sorafenib tosylate,
sildenafil citrate, celecoxib, cisplatin, carboplatin, and oxaliplatin) were purchased from
Selleck Chemicals in Houston, TX. Established cell lines of OVCAR3, SKOV3,
CAOV3, and PA1 were purchased from ATCC. The PDX models, including CTG1677
#1, CTG1677 #2, CTG1703 #1, CTG1703 #2, MCVH OP1, and the de novo
carboplatin/paclitaxel resistant Spiky, were procured from Karen Paz, PhD, the chief
scientific officer with Champions Oncology, NJ. The Mayo Clinic repository in
Rochester, MN provided the GBM cells. The cellular culture materials DMEM, MEM,
RPMI, penicillinstreptomycin, trypsinEDTA, βestradiol, insulin, and PBS were
purchased from GIBCOBRL (InvitrogenGIBCOBRL Life Technologies, Grand Island,
NY). The FBS used in this study was purchased from HyClone Laboratories, Inc
(Thermo Scientific Hyclone, South Logan, UT). The 4% paraformaldehyde in PBS came
from Alfa Aesar, a subsidiary of ThermoFisher Scientific. Both the calcein and the
ethidium homodimer1 used in live/dead assays came from Life Technologies, another
ThermoFisher Scientific subsidiary. Rat serum, DAPI, and DMSO were all purchased
from Sigma Chemical (St. Louis, MO). For transfections, the lipofectamine reagent and
OptiMEM came from ThermoFisher Scientific as well. The plasmid to express GRP78
was obtained by the Dent laboratory from the generous collaboration with A.S. Lee,
PhD of the University of Southern California in Los Angeles, CA. Other plasmids used in
this study were purchased from Addgene in a process governed by material transfer
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agreements. The Dent lab purchased all the validated siRNA from Qiagen (Valencia,
CA). Phospho and total primary antibodies used for immunofluorescence were
obtained from Cell Signaling Technologies (Danvers, MA) and from Santa Cruz Biotech
(Santa Cruz, CA). Secondary antibodies (IRDye 680LT GOat antirabbit IgG and IRDye
800CW Goat antimouse IgG) came from LICOR Biosciences (Lincoln, NE). The
Corning 96well plates came from Sigma Aldrich. Flasks and graduated tubes were
purchased from ThermoFisher Scientific. Core lab equipment such as the centrifuge
and tissue culture hood belong to Massey Cancer Center of Virginia Commonwealth
University. The tumor dissociator used in the study, the gentleMACS Dissociator, and all
enzymes used within that process, came from Miltenyi Biotec. Images shown for
live/dead assays as well as immunofluorescence were captured using the Hermes
WiScan unit from Accela, which was paid for through the generosity of the Betts family
fund.

Methods
Tumor Dissociation
The Spiky, MCVH OP1, CTG1703 #1, CTG1703 #2, CTG1677 #1, and
CTG1677 #2 are PDX cell lines isolated in the Dent lab. Prior to utilization in the course
of this research, the tumors were dissociated from the bulk tissue and established as
stable cancer cell lines. The protocol used was provided by Miltenyi Biotec, and is
detailed here. Enzymes used in this procedure are referred to by the name attributed to
them by Miltenyi Biotec.
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For the dissociation of ovarian tumors, all of which are deemed “soft” by Miltenyi
Biotec, an enzyme mix was prepared by adding 4.7 mLs DMEM, 200 μL of Enzyme H,
100 μL of Enzyme R, and 25 μL of Enzyme A into a gentleMACS C Tube. Concurrently,
the patient’s tumor was cut into small pieces (24 mm) using a simple scalpel. During
the cutting process, an attempt was made to remove any associated adipose, fibrous, or
necrotic areas from the tumor itself. The tumor sections were placed into the
gentleMACS C Tube containing the enzyme mix already prepared. The C Tube was
then closed and placed upsidedown into the designated slot in the gentleMACS
Dissociator. Once the program was complete, the C Tube was removed from the
0
gentleMACS Dissociator and incubated for 30 minutes at 37
C under continuous

rotation at 70 rpm. The C Tube was then placed upsidedown into the gentleMACS
Dissociator once again. At the end of the dissociator program, the tube was again
0
removed from the machine, and incubated for 30 minutes at 37
C under continuous

rotation at 70 rpm followed by a further treatment in the gentleMACS Dissociator.
The C Tube contents were filtered through a MACS SmartStrainer, 70 μm,
positioned over a standard 50 mL tube. The strainer was washed with 20 mLs of DMEM
to ensure the dissociated cells were all collected into the tube below. The 50 mL tube
was centrifuged at 300 g for 7 minutes. The supernatant was completely removed, and
the pellet resuspended in appropriate media. The dissociated cells were placed in a
sterile flask and cultured in the standard procedure detailed below.
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Cell Culture
SKOV3 cells were cultured in McCoy’s medium supplemented with 10%
(vol/vol) FBS and 100 μg/mL (1% vol/vol) penicillinstreptomycin. OVCAR cells were
cultured in RPMI medium supplemented with 20% (vol/vol) FBS, 100 μg/mL (1%
vol/vol) penicillinstreptomycin, and 1 mg/mL insulin. CAOV3 cells were maintained in
DMEM supplemented with 10% (vol/vol) FBS and 100 μg/mL (1% vol/vol)
penicillinstreptomycin. PA1 cells were cultured in MEM supplemented with 10%
(vol/vol) FBS and 100 μg/mL (1% vol/vol) penicillinstreptomycin. The PDX lines, Spiky,
MCVH OP1, CTG1677 #1, CTG1677 #2, CTG1703 #1, and CTG1703 #2, cells were
maintained in DMEM supplemented with 10% (vol/vol) FBS, 100 μg/mL (1% vol/vol)
penicillinstreptomycin, and 500 ng/mL βestradiol. All cells were incubated in a
0
humidified atmosphere of 5% CO
at 37
C.
2

Cell Counting and Plating
All the cells used in this study were adherent. Prior to use, cells were removed
from the adherent surface by trypsinization.
Cells were plated at different densities depending upon the assay. Cells were plated at
a density of 5.0 x 58 (per well of a 96well plate) for live/dead assays and at a density of
3
3.0 x 10
(per well of a 96well plate) for immunofluorescence. Cells were allowed to

adhere to the well surface under standard incubation conditions for 2430 hours prior to
treatment.
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Drug Treatment
Drug concentrations used in this study were selected based upon previous
studies published by the Dent laboratory. The concentration of each drug used in this
study was as follows: sorafenib, 2 μM, sildenafil, 2 μM, celecoxib, 5 μM, unless
otherwise noted. The platinum drugs, cisplatin, carboplatin, and oxalipatin, 2 μM. Drug
solutions were prepared fresh from powder drug and solubilized in DMSO. Final drug
dilution for addition to cells was in the appropriate cell culture media. Solvent
concentration did not exceed 0.1% in final drug dilutions.

Transfections of plasmid and siRNA
For the transfection of both plasmids and siRNA plated on the 96well plates, 2
μL (per a transfection of 16 wells) of each plasmid was added to 200 μL of OptiMEM
and incubated in solution for 5 minutes at room temperature. Concurrently, 2 μL (per a
transfection of 16 wells) of lipofectamine was added to 200 μL of OptiMEM in a
separate graduated tube, and also allowed to sit for 5 minutes. After 5 minutes, the
contents of the two tubes were mixed into a single tube, and then incubated for 20
minutes at room temperature.
1.6 mL (per a transfection of 16 wells) of the relevant FBS supplemented media
was added to the transfection solution. 100 μL of the solution was added to each well on
the plate. The transfected plates were then incubated under standard incubation
conditions for 24 hours prior to drug treatment or data acquisition.
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Immunofluorescence
To prepare a plate for image acquisition of fluorescenttagged proteins, the
media was removed from each of the wells on the plate. 100 μL 4% paraformaldehyde
was added to each well to fix the cells, and the plate was incubated under standard cell
culture conditions for 20 minutes. The 4% paraformaldehyde was removed, and the
cells were washed with 100 μL PBS twice. A 10% rat serum solution was made with
PBS, and added to the cells as a blocking buffer. The fixed cells were placed in a cold
room for 24 hours. Blocking buffer was removed and primary antibodies were added to
the plate in a 10% rat serum solution. The plates were returned to the cold room
overnight. The plates were washed with PBS to remove any unbound primary antibody.
The secondary antibody was added in 10% rat serum solution, and left overnight. A final
wash with PBS was done, and a rat serum solution with DAPI added.
The plate was then loaded onto the Hermes WiScan machine and viewed for
fluorescence. All images recorded were saved to the local hardware and a removable
flash drive.

Live/Dead Assay
To determine the effectiveness of a given drug treatment on the killing of cancer
cells, a Live/Dead assay was performed using the Hermes WiScan machine.10
mLs/plate FBS was prepared with 5 μL calcein (shows live cells) and 5 μL ethidium
bromide (shows dead/dying cells) as a live/dead solution. The live/dead solution was
added to the plate in a volume of 100 μL/well. The plate was centrifuged at a rate of
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800 rpm for 3 minutes, and loaded into the Hermes WiScan for image acquisition.
Images taken were a representative sample from all wells.
Percentages of cell death were determined by a simple count of the cells within
the collected image.

Data Analysis
Data shown is representative of at least three groups receiving the experimental
condition. Representative images were collected from each group, and one was
selected for presentation within this thesis. The various treatments were analyzed for
statistical significance using a oneway analysis of variance and a twotailed Student’s
t
test. Results with a pvalue <0.05 were considered statistically significant.

Results
The three drugs used as the combination targeted therapy in this study were
sorafenib (referred to as sor), sildenafil (referred to as sil), and celecoxib (referred to as
cel). The three drugs have been utilized individually, and as a part of a combination, in
multiple clinical trials and previous studies, as anticancer agents. Sorafenib and
104
sildenafil have shown particular promise as a drug diad at a concentration of 2 μM.
As

such, and with the intent to use celecoxib as part of the triad, a concentration dose
response was performed in OVCAR and SKOV3 cells to determine a role for cel within
its clinically relevant range. OVCAR and SKOV3 are established cell lines which are
resistant to the standard of care, cisplatin. Both OVCAR and SKOV3 cells responded
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to the triad in a greater than additive fashion (p<0.05). In OVCAR cells, the
sorafenib/sildenafil lethality was increased at concentrations of celecoxib as low as 12
μM (Figure 11A,B). SKOV3 cells proved to be less responsive to the triad, but cell
death was seen at 3 μM celecoxib (Figure 11A,C). As a result, both sildenafil and
sorafenib continued to be used at a concentration of 2 μM, and celecoxib was used at 5
μM unless otherwise stated.
To assess the specific cell killing potential of celecoxib/sildenafil and
sorafenib/sildenafil, and to verify that the triad’s effects were replicable across multiple
cell lines, a live/dead assay was performed. MCVH OP1 (a PDX line), CAOV4, and
CAOV3 (both established cell lines with p53 mutations) were treated with vehicle
(DMSO), and a combination of either sorafenib and sildenafil, celecoxib and sildenafil,
or celecoxib, sorafenib, and sildenafil for 24 hours (Figure 12). Viability was determined
by the Hermes WiScan system. The patient derived cells, MCVH OP1, were the most
sensitive to the triad while CAOV4 and CAOV3 still had greater than additive
differences in death over the control (p<0.05)(Figure 12A,B). The last established cell
line to be tested was PA1 (with an NRas mutation). After 24 and 48 hours of drug
treatment, cell viability was assessed using the Hermes WiScan. Cell death in the triad
group was significantly higher than that of either the diads or the vehicle (p<0.05)(Figure
13A,B).
Other PDX cell lines established in the Dent lab were assessed for sensitivity to
the drug combination. One such line was called Spiky. Spiky showed a significant
response in cell death to each drug diad at both the 24 and 48 hour timepoints (p<0.05),
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but did not show a significant increase in response when treated with the triad. (Figure
13A, B).
Four additional PDX lines of unknown genetic characteristics were used in this
study. Interestingly, despite originating from the same patient, isolates sent to the Dent
lab after having been tumorized in mice often responded differently to treatments. As
such, they are referred to as separate lines resulting in CTG1677 #1, CTG1677 #2,
CTG1708 #1, and CTG1708 #2, respectively. The four lines were treated with the
standard drug concentrations of veh, sor/sil, cel/sor, and CSS for 24 hours and
assessed for cell viability using the Hermes WiScan. Neither CTG1677 #1 nor #2
showed significant death at 24 hours. CTG1708 #1 had a less than significant
response, while CTG1708 #2 had a significant response to the drug triad over vehicle
(p<0.05)(Figure 14A,C). After 48 hours, CTG1677 #1, CTG1677 #2, CTG1708 #1,
and CTG1708 #2 all exhibited cell death as a result of the triad over vehicle (p<0.05)
(Figure 14 B,D).
Considering that all cell lines exhibited a response to the drug combination, the
drugs and concentrations described above were used throughout this study. All lines
tested had some response to the combination, and were used in this study accordingly.
SKOV3 served as a model of resistance in terms of cell death to both the
combinational therapy and platinum drugs. OVCAR3 was used as a triad sensitive,
cisplatin resistant line. PA1 is killed by platinums, and also had a profound response to
the drug triad (p<0.05). Each of the PDX lines was continuously used with the exception
of MCVH OP1.
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Figure 11. Celecoxib dose response in OVCAR and SKOV3 cells. 
OVCAR and
SKOV3 cells were treated with 2 μM sorafenib and sildenafil, and varying
concentrations of celecoxib within the clinically relevant range, as indicated above. (A)
Cell viability was determined by live/dead assays using the Hermes WiScan system
after 24 hour drug exposure.Images shown are representative of each experimental
group. This data was quantified for (B) OVCAR and (C) SKOV3 and presented
graphically
46

Figure 12. Assessment of cell viability in multiple ovarian cancer cell lines treated
with combinational drug therapy. 
MCVH OP1, CAOV4, and CAOV3 were treated
with 2 μM sorafenib, 2 μM sildenafil, and 5 μM celecoxib for 24 hours. (A) Cell viability
was determined by live/dead assays using the Hermes WiScan system.Images shown
are representative of each experimental group. (B) This data was quantified for all three
cell lines and is presented graphically
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Figure 13. Assessment of cell viability in Spiky and PA1 cell lines treated with
combinational drug therapy. 
Spiky and PA1 cells were treated with 2 μM sorafenib, 2
μM sildenafil, and 5 μM celecoxib for 24 and 48 hours. Cell death percentage shown is
for 48 hour treatment. (A) Cell viability was determined by live/dead assays using the
Hermes WiScan system.Images shown are representative of each experimental group.
(B) This data was quantified for both cell lines and is presented graphically
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Figure 14. Assessment of cell viability in PDX cell lines treated with
combinational drug therapy. 
CTG1677 #1, CTG1677 #2, CTG1703 #1, CTG1703
#2 were treated with 2 μM sorafenib, 2 μM sildenafil, and 5 μM celecoxib. Cell viability
was determined by live/dead assays using the Hermes WiScan system at (A) 24 hours
and (B) 48 hours after treatment.Images shown are representative of each experimental
group. This data was quantified for both cell lines and is presented graphically for both
the (C) 24 and (D) 48 hour timepoints.
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The role of cellular efflux pumps ABCB1 and ABCG2 on celecoxib, sorafenib, and
sildenafil toxicity.

To determine the mechanism by which the drug combination causes cell toxicity,
cellular efflux pumps were examined. Increased expression of plasma membrane
associated ABCB1 and ABCG2 are a wellestablished mechanism of chemotherapeutic
resistance. ABCB1 and ABCG2 are able to cause sorafenib efflux from the cell. I
hypothesized that the drug combination may work, to a degree, by inhibition of these
pumps. A dose response experiment was performed with 2 μM sorafenib and 2 μM
sildenafil and a concentration range of celecoxib. OVCAR and SKOV3 cells were used
as they are established lines with known resistance to chemotherapy. In OVCAR and
SKOV3, the sorafenib/sildenafil diad was able to decrease ABCB1 and ABCG2
expression over the vehicle even without celecoxib (Figure 15 A,B,C,D). OVCAR pump
levels were further inhibited with increasing concentrations of celecoxib (Figure 15 A,B).
SKOV3 exhibited a change of ABCB1 expression after the addition of 1 μM celecoxib,
but increased levels of celecoxib did not have an effect past a dose of 2μM (Figure 15
C,D).
Chaperone protein HSP27 is, in part, an upstream regulator of cellular efflux
pumps. With an interest in chaperones, and efflux pumps, this study utilized
immunofluorescence to visualize HSP27 expression following 6 hours exposure to the
combinational drug treatment. In Spiky, OVCAR, CAOV3, and PA1 HSP27 levels were
reduced following treatment (Figure 16).
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To further explore the link between chaperone proteins and cellular efflux
proteins, GRP78 and HSP27 were overexpressed individually and in combination in
Spiky and OVCAR. The transfected cells were then subjected with CSS used for the
first time or veh. Overexpression of the chaperone proteins prevented the drug
combination from reducing the expression of ABCB1 and ABCG2 (Figure 17A).
As the final assessment of the role of cellular efflux pumps in CSS mechanistic
killing, the potent pumpinhibitor drug, elacridar (referred to in the figure as “Pi”), was
administered to SKOV3 and OVCAR cells along with CSS. The addition of Pi did not
have a significant effect on the lethality of CSS in either SKOV3 or OVCAR cells after
12 hours of treatment (Figure 17B). While the drugs have an effect on cellular pump
expression, they do not completely knockout ABCB1 or ABCG2. Since the potent Pi, did
not increase cell death in the presence of CSS, the data suggests that alteration of
pump expression or function does not fully explain how CSS can kill ovarian cancer
cells.
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Figure 15. Celecoxib dose response on ABCB1 and ABCG2 in OVCAR and
SKOV3 
OVCAR and SKOV3 cells were treated with 2 μM sorafenib and sildenafil,
and varying concentrations of celecoxib within the clinically relevant range for 24
hours.Images shown are representative of each experimental group. Proteins of
interest are tagged with red fluorescent antibodies. Cell nuclei are stained blue with
DAPI. (A) ABCB1 and (B) ABCG2 expression was assessed in OVCAR cells. (C)
ABCB1 and (D) ABCG2 expression was assessed in SKOV3 cells
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Figure 16. Immunofluorescent HSP27 expression after drug combination 
Spiky,
OVCAR, CAOV3, and PA1 cells were treated as indicated for 6 hours. HSP27
expression is shown in green on the left with DAPI staining on the right.Images shown
are representative of each experimental group.
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Figure 17. Assessment of efflux pump modulation/function. 
(A) Spiky and OVCAR
cells were transfected to overexpress GRP78, HSP27, GRP78+HSP27, or scramble as
indicated. Cells were then treated with the drug combination or veh for 24hr and fixed
for immunofluorescence. Cells were then probed for ABCB1 and ABCG2 expression.
Proteins of interest are tagged with red fluorescent antibodies.(B) OVCAR and SKOV3
cells were treated with veh or css and veh or pump inhibitor drug, elacridar, for 12 hr.
Live/dead was performed to determine cell viability.Images shown are representative of
each experimental group.
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The unfolded protein response (UPR) plays a role in CSS toxicity.
OVCAR cells were transfected with siRNAs to inhibit essential proteins of the
unfolded protein response. The UPR proteins targeted by siRNAs included PKRlike
endoplasmic reticulum kinase (PERK) and its downstream effectors activating
transcription factor 4 (ATF4), and C/EBP homologous protein (CHOP). The cells were
treated with CSS for 24 hours. Results indicated that knockdown of PERK, ATF4, and
CHOP decreased CSS induced cell death (Figure 18 A,B).
To further assess role of the UPR in the CSS mediated cell death, the study
examined GRP78 and peIF2α expression. GRP78 (or BiP) is a chaperone protein
whose dissociation from PERK is responsible for the initiation of one branch of the UPR
cascade which then phosphorylates eIF2α to affect transcription factors which can halt
translation as well as potentiate the cell for apoptosis. Using immunofluorescence, after
just 6 hours of treatment with CSS, Spiky cells showed a reduction in GRP78
expression, and an increase in peIF2α (Figure 19A). To verify these results, Spiky and
OVCAR cells were both treated for 12 hours with CSS and probed for GRP78 and
peIF2α under immunofluorescence. Spiky cells continued to show CSS mediated
inhibition of GRP78 expression (Figure 19B) and increase in peIF2α (Figure 19C).
Ovcar showed the same trend of lowered GRP78 expression (Figure 19D) and of
increased peIF2α (Figure18E).
OVCAR and Spiky cell lines were transfected with either siRNA for scramble
(SCR), GRP78, or sieIF2α followed by treatment for 12 hours with the drug regimen.
Both cell lines were analyzed using the Hermes WiScan. Results indicated that the SCR
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group showed a significant increase in killing in the CSS group over the VEH group
(p<0.05)(Figure 20A,B,C). Knockdown of GRP78 increased the amount of CSS
mediated killing in both cell lines (p<0.05)(Figure 20A,B,C). Knockdown of eIF2α
significantly reduced the cell death induced by the drug combination in both cell lines
compared to SCR (p<0.05)(Figure 20A,B,C).
The above results indicate that the UPR is heavily involved in the celecoxib,
sorafenib, sildenafil mediated killing of ovarian cancer cells 
in vitro
. Specifically, drug
inhibition of GRP78 may increase the phosphorylation of PERK and the subsequent
phosphorylation of eIF2α. Continued stress caused by the drug combination used in this
study may induce apoptosis through ATF4 activation of CHOP.
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Figure 18. Cell death mechanism determination 
(A, top) OVCAR cells were treated
for 24hr and then assessed for viability. (A, bottom, left) OVCAR cells were transfected
with the indicated siRNAs and then treated with the drug combination. Viability was
determined after 24 hours. (A,bottom,right) IF of designated proteins as indicator of
successful transfection.Images shown are representative of each experimental group.
Proteins of interest are tagged with red fluorescent antibodies.(B) Quantification of cell
death after transfections and treatment in A.
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Figure 19. Immunofluorescence of GRP78 and peIF2α 
Spiky and OVCAR were
treated as indicated for 6 hours or 12 hours. Proteins of interest are tagged with red
fluorescent antibodies. Cell nuclei are stained blue with DAPI. (A) GRP78 and peIF2α
expression after drug treatment in Spiky cells. (B) GRP78 expression in Spiky cells after
12 hour treatment. (C) peIF2α expression in Spiky cells after 12 hour treatment. (D)
GRP78 expression in OVCAR cells after 12 hour treatment. (E) peIF2αexpression in
OVCAR cells after 12 hour treatment.Images shown are representative of each
experimental group.
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Figure 20. Cell viability following transfection with siGRP78 or sieIF2α 
(A) Spiky
and OVCAR were transfected with the indicated plasmid, then treated with the drug
combination for 12 hours. Images shown are representative of each experimental
group. The results were quantified for and represented graphically for (B) Spiky and (C)
OVCAR.
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Assessment of apoptotic role of CSS killing
Assessment of results concerning chaperone proteins and the UPR, apoptosis
was implicated as the effector of CSS mediated killing. Active eIF2α leads to an
activated CHOP which inhibits antiapoptotic proteins such as Bcell lymphoma
extralarge (BCLXL), myeloid leukemia cell differentiation protein (MCL1), and cellular
FLICEinhibitory protein short (cFLIPs). Knockdown of these three proteins leads to
the cleavage of procaspase 3 to yield the proapoptotic cleaved caspase 3. To assess if
CSS act to kill through apoptosis via an eIF2αdependent manner, OVCAR and Spiky
were transfected with siRNA for SCR or sieIF2α, followed by treatment with CSS
(Figure 21A). Protein expression was assessed through immunofluorescence. Within
the SCR siRNA group of both cell lines, CSS treatment led to a decreased expression
of antiapoptotic proteins cFLIPs, BCLXL, and MCL1 in both OVCAR and Spiky, with
a greater down regulation seen in OVCAR (p<0.05)(Figure 21A). Predictably, the
decrease in antiapoptotic proteins was coupled with an increase in cleaved caspase 3
(Figure 21A). The endogenous expression of the antiapoptotic proteins in the vehicle
group was much higher (p<0.05) in the cells transfected with siRNA for eIF2α than in
the cells transfected with SCR siRNA (Figure 21A). Conversely, the endogenous
expression of cleaved caspase 3 was lower in cells transfected with siRNA for eIF2α
when compared to cells transfected with SCR siRNA (Figure 21A). When eIF2α was
knocked down, the expression of antiapoptotic proteins assessed in this study was not
inhibited to the same extent by drug treatment in either cell line when compared to cells
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not transfected with siRNA for eIF2α (Figure 21A). Interestingly, cleaved caspase 3
recruitment was minimally affected in sieIF2α(Figure 21A).
Transfections with siRNA for EIF2α was shown to significantly down regulate the
endogenous expression of the antiapoptotic proteins investigated in this study in
OVCAR cells. Overexpression of BCLXL, MCL1, and cFLIPs in OVCAR cells was
shown to protect cells from the cell death induced by CSS (Figure 21B). Cells were
infected with a dominant negative caspase 9. Following infection, cells were treated 12
hours with CSS. Cell viability was determined using a Live/Dead assay on the Hermes
WiScan. (Figure 21B). Cells infected to overexpress the antiapoptotic proteins were
significantly (p<0.05) protected from CSS induced cell death. Similar results were seen
for the cells infected with dominant negative caspase 9 (Figure 21B,C). Of note, the
overexpression of antiapoptotic proteins did not affect a decrease in cell numbers seen
following drug treatment.
The presence of CSSmediated cell death following modulation of proteins
involved in apoptosis suggests a potential for additional mechanism(s) of killing. A part
of the cell death seen in these studies may be caused by necrosis, and was thus
examined in this study. Receptorinteracting serine/threonineprotein kinase 1 (RIP1) is
an upstream regulator of necrosis. As such, it was knocked down via siRNA to RIP1 in
order to determine the role for necrosis in the killing mechanism of CSS. Using the
same design as above, with 12 hour drug treatment after transfection, knockdown of
RIP1 was shown to significantly reduce drug induced cell death (p<0.05)(Figure 22A).
Downstream from RIP1 in the necrotic pathway are BH3 interactingdomain death
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agonist (BID) and caspases 2 and 4. When BID or caspase 2 and caspase 4 were
knocked down via siRNA, both Spiky and OVCAR cells were protected from CSS
toxicity (Figure 22B). These results implicate that necrosis plays a part in the
mechanism of CSS in ovarian cancer cell killing.
To determine a role for autophagy in the cell death induced by CSS, key
autophagic proteins Beclin1 and ATG5 were knocked out via siRNA transfection in
OVCAR and SKOV3 cells prior to CSS treatment. Results suggested that autophagy
does not play a significant role in the cell death induced by CSS (Figure 22C).
The above results suggest CSS acts via stressing the ER of the treated cells,
thus triggering the UPR, and overwhelming the same to prompt the cell to enter
apoptosis. Concurrently, the CSS treated cell is undergoing the more chaotic route of
necrosis.
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Figure 21. Assessment of apoptotic involvement in CSS mediated killing 
(A, top)
Spiky and OVCAR cells were transfected with either empty plasmid (SCR) or siEIF2α,
and then treated with either vehicle or the drug combination. After 12 hours, the cells
were probed for the indicated proteins with red fluorescent antibodies. (A,bottom)
Indication of successful inhibition of eIF2α. (B) Live/Dead assay for cell viability
following transfection/treatment as indicated in OVCAR cells. (C) The results were
quantified for and represented graphically. Images shown are representative of each
experimental group.
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Figure 22. Assessment of necrotic and autophagic involvement in CSS mediated
killing 
(A, left) OVCAR cells were transfected with either empty plasmid (SCR) or
siRIP1, and then treated with either vehicle or the drug combination. After 12 hours, a
live/dead assay was performed and quantified. (A,right) Indication of successful
inhibition of RIP1. (B, top) Live/Dead assay for cell viability following
transfection/treatment as indicated in OVCAR and Spiky cells after 24hr drug treatment.
(B, bottom) Indication of successful inhibition of BID, Casp2, and Casp4. (C, left)
Live/Dead assay for cell viability following transfection/treatment as indicated in OVCAR
and Spiky cells after 12hr drug treatment. (C, right) Indication of successful inhibition of
Beclin1 and ATG5
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Impact of drug combination on signal transduction pathways linked to tumor
growth/invasion and chemotherapeutic resistance.
The next goal of this study was to determine the effect of celecoxib, sorafenib,
and sildenafil combination therapy on wellknown signal transduction pathways linked to
cancer growth, invasion, and resistance to chemotherapeutics. Spiky cells were treated
for six hours with either DMSO as the vehicle or CSS. The cells were then probed for
proteins of interest within the signaling pathways. JNK expression was investigated due
to its role in promoting apoptosis and by virtue of JNK expression being indirectly
105
increased through sildenafil.
Cel/Sil had a noticeable upregulatory effect on the

expression of phosphorylated JNK. This effect was also seen in the triplicate group
(Figure 23A). Signal transducer and activator of transcription (STAT) proteins are
antiapoptotic transcription factors essential to the survival of many cancers. AKT is a
welldocumented antiapoptotic protein which is indirectly inhibited by celecoxib.
Accordingly, STAT3, STAT5, and AKT were probed as part of this assay. While the total
STAT5 and total AKT expression remained constant across the treatment groups, the
phosphorylated forms of the proteins were suppressed by the drug triad (Figure 23A).
Of note, active STAT5, a transcription factor, was blocked by both diads, and the
triplicate (Figure 23A). Active STAT3 levels were decreased by treatment with CSS
(Figure 23A). However, STAT3 was not decreased by either diad. The final transcription
factor probed was phosphorylated p65 NFκB, which was significantly inhibited by the
sor/sil diad compared to veh, an effect more significant in CSS compared to the veh.
(Figure 23A). Lastly, expression of phosphoERK was examined due to its role as an
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antiapoptotic protein downstream of the sorafenib target, Raf. Following the trend,
while PERK was slightly inhibited by sor/sil, the most drastic effect was in the triad
group where the PERK expression was more inhibited (Figure 23A).
With an idea of some of the pathways affected by CSS treatment, we next sought
to further determine their involvement by observing their effects on cell viability. As
such, OVCAR and Spiky cells were plated and treated inhibitory peptide of JNK,
infected with a dominant negative IkB kinase (IKK), or constitutively active forms of
STAT3. MEK1, or AKT. Inhibition of JNK was shown to significantly (p<0.05) protect
Spiky and OVCAR cells from cell death (p<0.05) (Figure 23 B,C,D). As expected,
constitutively activating STAT3, MEK1, or AKT was protective for both OVCAR and
Spiky cells (p<0.05) (Figure 23 B,C,D). IKK is an inhibitor of NFκB. Infection of cells
with dominant negative IKK was expected to lead to an increase in cell death, and in
Spiky it did (p<0.05)(Figure 23 B,D). However, OVCAR cells did not show any decrease
in cell viability, and IKK demonstrated a very mild protective effect in OVCAR cells
(Figure 23 B,C). It is likely IKK, thus NFκB, are insignificantly affected by CSS, and this
apparent protection could be attributed to simple variability between treatment groups.
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Figure 23. Assessment of drug triplicate on signaling pathways 
(A) Spiky cells
were treated with the indicated drugs for 6 hours, and then probed for proteins of
interest with red fluorescent tags. DAPI stained the nuclei blue to serve as point of
reference. (B) OVCAR and Spiky cells were transfected and treated as indicated. After
24 hours, cell death was determined using a Live/Dead assay. Images shown are
representative of each experimental group. Results of the Live/Dead were quantified
and graphed for (C) OVCAR and (D) Spiky
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Celecoxib, sorafenib, sildenafil mediated resensitization to platinum standard of
care drugs.
The main aim of this study was to determine if combinational drug therapy would
prove an effective treatment against platinum resistant ovarian cancer lines, ideally
resensitizing those same lines to the standard of care drugs once again. Towards this
aim, PA1,CAOV3, SKOV3, and Spiky were plated. PA1 and CAOV3 were chosen
due to having different oncogenic mutations. SKOV3 was chosen due to being an
established cell line with cisplatin resistance. Spiky was chosen as it is a PDX line with
de novo
platinum resistance. All four lines were treated with either DMSO (vehicle) or
the CSS triplicate for 12 hours. Half of the vehicle group for each cell line received
DMSO (vehicle) while the other half received cisplatin. Similarly, twelve hours after
initial treatment half of the CSS group received DMSO while the other half received
cisplatin. All four groups in each of the four lines were then incubated for twelve hours,
at which point a live/dead assay was performed. As seen previously, Spiky and
SKOV3 cells exhibited significant (p<0.05) increases in cell death compared to control
cells (Figure 24 A,B). PA1 and CAOV3 cells showed significant levels of cell death
with just CSS compared to the control cells (p<0.05) (Figure 24 A,B). However, CSS
treatment significantly increased cisplatin toxicity in Spiky, PA1, and CAOV3 cells
(p<0.05) (Figure 24 A,B). SKOV3 showed no significant response to either the triad
alone or the triad mediated cisplatin (Figure 24 A,B).
OVCAR cells were chosen for our next assay as SKOV3 cells did not respond
to the CSS/cisplatin treatment, and OVCAR are also an established cell line with
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cisplatin resistance. Our next step was to determine whether CSS works only in
combination with cisplatin as a fourth drug, or if CSS was actually resensitizing the
cancer cells to cisplatin. The cells were treated for six hours with DMSO (vehicle),
cel/sil, sor/sil, or CSS. Drug was removed, and the cells washed with PBS, at which
point cisplatin or DMSO (vehicle) was added for 18 hours. By the end of the total 24
hour period, there was no significant difference between the cells which had been
treated with CSS for 6 hours and then DMSO to those which had only been treated with
DMSO (p<0.05) (Figure 24 C,D). There was significant cell death (p<0.05) in the group
which had been exposed to CSS for just six hours, and then cisplatin for a further 18
hours (Figure 24 C,D).
Cisplatin was the first of the platinum based chemotherapeutics, but is not the
only one in use today. Carboplatin and oxaliplatin are both also used, and are generally
tolerated better by patients than cisplatin. We sought to determine if CSS was able to
potentiate platinumbased killing for the other platinum drugs. PA1 and CAOV3 were
chosen as neither are platinum resistant, so any CSS potentiation should be more
distinct. The cells were treated with either a singular platinum drug for twelve hours, or
the platinum drug along with CSS. While showing some level of cell death, the platinum
drugs alone were not significantly effective (Figure 25 A,C). In both PA1 and CAOV3
cells, however, both cisplatin and carboplatin were able to increase the percentage of
cell death as compared to the platinum drug alone (Figure 25 A,B,C). Interestingly,
cisplatin was more effective than carboplatin against CAOV3 cells whereas the

77

opposite was true for PA1 cells (Figure 25 A,B,C). Oxaliplatin exhibited essentially no
effect in either cell line regardless of the addition of CSS (Figure 25 A,D).
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Figure 24. Assessment of drug triad effect on sensitization to cisplatin 
(A) Spiky,
PA1, SKOV3, CAOV3 were treated with 2 μM sorafenib, 2 μM sildenafil, and 5 μM
celecoxib. 12 hrs after the initial treatment, the indicated treatment was added for 12
additional hours. Total drug treatment time was 24 hours. Cell viability was determined
by live/dead assays using the Hermes WiScan system. Images shown are
representative of each experimental group. (B) This data was quantified for all cell lines
and is presented graphically. (C) OVCAR cells were treated with the indicated drug
combination for 6 hrs. At that time, the drug was removed, and the cells were washed
with PBS. Either DMSO or cisplatin was then added for an additional 18 hours at which
time cell viability was determined by live/dead assay using the Hermes WiScan system.
Images shown are representative of each experimental group. (D) This data was
quantified and is presented graphically.
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Figure 25. Assessment of drug triad effect on sensitization to platinum drugs
PA1 and CAOV3 were treated with either a platinum drug for 12 hours, or a platinum
drug in combination with celecoxib, sorafenib, and sildenafil (CSS). (A) Cell viability was
determined by live/dead assays using the Hermes WiScan system. Images shown are
representative of each experimental group. (B) This data was quantified for cisplatin
(CIS) sensitization (C) This data was quantified for carboplatin (CARBO) sensitization.
(D) This data was quantified for oxaliplatin (OX) sensitization
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Discussion
Women facing ovarian cancer today must confront bleak realities of common
relapses, and chemotherapy desensitized tumors. This is often due to the acquired
resistance of the tumor cells to platinum based drugs. While the initial response rate to
platinums of 70% of women experiencing tumor reduction sounds promising, the sad
1,93
reality is that only 45.6% of women survive five years after their diagnosis.
The main

theories of how ovarian cancer becomes resistant to platinum drugs center around
intracellular drug reduction, accumulation of thiols, and upregulation of prosurvival
93,44,46
pathways.
The Dent lab has published multiple studies detailing multiple drug

targeted therapy mediated death on otherwise hardy cell lines. As such, the aim of this
study was to potentially develop a novel therapeutic drug treatment for ovarian cancer.
The first step in this process was identifying potential drugs which may prove
effective against ovarian cancer. The multikinase and Raf inhibitor sorafenib has been
demonstrated to be an effective treatment against multiple tumor types as an individual
treatment, the results of which are amplified by the PDE5 inhibitor, sildenafil. 78,104

Additionally, celecoxib has shown to inhibit the otherwise overexpressed AKT pathway
110,63
in cancer cells.
Again, the Dent lab has demonstrated the greater than additive cell
15
death of celecoxib with sildenafil over either drug singularly.
The present study also

was inclined to use these three drugs as they are generally welltolerated, and either
currently are, or about to be losing patent protection. Thus, the proposed combinational
therapy would be more financially accessible for patients as well.
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We were able to show early on in the study that our combination of 2 μM
sorafenib and 2 μM sildenafil was effective in combination with 3μM celecoxib for killing
platinum resistant ovarian cancer cells (Figure 11). Once the drug combination
demonstrated a capacity to increase the cell death against the two initial platinum
resistant lines, the combination was tested against most established wellestablished
lines currently available as well as against PDX lines isolated within the Dent lab for the
purposes of this study (Figure 12, 13, 14).
Our next step was to elucidate the potential mechanisms by which the drug triad
was causing cell death. To do this, we examined the typical pathways by which ovarian
cells generally gain resistance to platinum drugs. In a previous study, Shi 
et al91
outlined
how sildenafil reverses the cellular efflux pumps’, ABCB1 and ABCG2, ability to
contribute to chemotherapeutic resistance in cancer cells. The increased activity of
these two types of pumps are part of the system which results in a reduced intracellular
91
drug concentration.
We were able to demonstrate that CSS inhibited ABCB1 and

ABCG2 expression in both OVCAR and SKOV3 cells (Figure 15). Similarly, chaperone
proteins associated with increased cell survival through both UPR and efflux pump
expression were inhibited by CSS treatment (Figure 16, 17A). Interestingly, however,
the highly potent pump inhibitor drug, elacridar, administered in combination with the
drug triad had a negligible effect on cell death, so it is unlikely efflux pumps are solely
responsible for CSS mediated death (Figure 17B).
Chaperone proteins, already shown to be suppressed by the experimental
treatment, play an integral role in the unfolded protein response. Since the efflux pumps
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were only partially responsible for the observed death, the UPR was examined next.
After transfection to inhibit crucial UPR proteins downstream of the chaperone protein
GRP78, the drug combination had a significantly diminished killing capacity as
demonstrated in Figure 18. If inhibition of specific proteins involved in the UPR was to
be implicated in the CSS mechanism differences in protein expression had to be
demonstrated. Figure 19 demonstrates that increased phosphoeIF2α expression is
increased concurrently with reduced expression of GRP78. These results are not
surprising as GRP78 dissociation with PERK is what leads to phosphorylation of
113
eIF2α.
To further verify these results, both GRP78 and eIF2α were knocked down.

Expectedly, the presence of the triad drug combination in the absence of GRP78
significantly increased the amount of cell death, whereas removing the prodeath
pathway of eIF2α protected cells against the triad (Figure 20). Based upon these
findings, we concluded that the UPR is heavily involved in the drug combination toxicity
to ovarian cancer cells, specifically the PERK pathway.
Downstream of active eIF2α, the cell activates CHOP whose effectors inhibit
15 
antiapoptotic proteins to trigger apoptosis.
In the presence of CSS, expression of

antiapoptotic cFLIPs, BCLXL, and MCL1 were significantly decreased compared to
control while the proapoptotic cleaved caspase 3 was significantly increased (Figure
21). When eIF2α was experimentally knocked down by siRNA, the antiapoptotic
proteins MCL1, BCLXL, and cFLIPs were expressed even in the presence of CSS
(Figure 21). When the antiapoptotic proteins were overexpressed experimentally, the
CSS mediated cell death was decreased significantly, but not totally blocked (Figure
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21), which suggested the drug combination acts through more than just apoptosis to kill
cells.
Necrosis is essentially the chaotic alternative to apoptosis for a dying cell. RIP1,
BID, and Caspases 2 and 4, all necrotic drivers, were experimentally knocked down
using specific siRNAs to determine the potential of necrosis as the missing mechanistic
source of cell death. Since both cell lines with an inhibited necroptotic pathway were
protected from CSS, the drug treatment must kill, in part, through necrosis (Figure 22).
In previous studies from the Dent lab, sorafenib and sildenafil, or celecoxib and
15,14,104
sildenafil have been shown to increase the levels of autophagosomes within cells.

Autophagy is an initially protective cellular response to recycle unnecessary or
inoperational cellular components. However, autophagy can lead to apoptosis if the
cellular stress causing the autophagy is not eased. As a result, apoptosis activity was
examined in this study, but found to play essentially no role in this particular drug
mediated killing (Figure 22). Thus, it appears that CSS kills ovarian cancer through both
apoptosis and necrosis directly, but has little impact on triggering the adaptive
autophagy. It is yet to be determined whether apoptosis or necrosis plays more of a role
in CSS mediated cell death.
The final mechanistic goals of this study were to determine where the drugs used
were affecting signal transduction pathways within the cell to begin the stress which
ultimately leads to apoptosis and necrosis. Sorafenib acts to inhibit multiple tyrosine
kinase receptors as well as Raf, both of which lead to the activation of ERK, which
78
serves as a prosurvival kinase.
Celecoxib, as an NSAID, directly inhibits COX2, an
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28
essential enzyme in the formation of prostaglandin E2 (PGE2).
However, celecoxib is

of interest to this study due to the ability to prevent PI3K from activating PDK1/2, thus
28
preventing AKT activation.
Sildenafil is a PDE5 inhibitor, which prevents the

degradation of cGMP, thus leading to an increase in active PKG, and, in parallel, a
116,99
triggering of the MEKK1/MKK/JNK cascade.
Both of these pathways lead to

apoptosis. The antiapoptotic active forms of AKT and ERK were both significantly
decreased in the presence of the CSS treatment (Figure 23A). Also, pJNK increased
with administration of CSS (Figure 23A). The data also showed a protective result when
the specific drug targets were constitutively activated (Figure 23 B,C,D). These results
verified the precise interactions of the three drugs within signal transduction pathways.
With platinum resistance such a problem in the treatment of ovarian cancer, a
main goal of this study was to develop an experimental treatment to complement the
standard of care, and potentially resensitize resistant tumors to platinum. Knowing the
general mechanism of CSS killing, we then treated lines both with and without
resistance with the drug combination and cisplatin. While SKOV3 cells showed a
negligent difference in cell death between the treated and control groups, the 
de novo
platinum resistant PDX cell line, Spiky, showed a significant increase in death in the
treated group, as did the other lines tested. (Figure 24 A,B). Not satisfied with simply
adding cisplatin to the triad therapy, we decided to see if we could achieve a true
resensitization of cells to cisplatin. Even after a brief exposure to CSS, and then total
removal of the drug combination prior to cisplatin administration, we were able to
demonstrate a significant increase in cell death in the group treated with cisplatin after
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CSS over the group which only received CSS (Figure 24 C,D). This data suggests we
had truly resensitized these platinum resistant cells to the standard of care therapy.
Since cisplatin is not the preferred platinum drug in use today, we tested its derivatives,
oxaliplatin and carboplatin. While cells displayed an apparent resensitization to
carboplatin postCSS treatment, those treated with oxaliplatin showed no apparent cell
death (Figure 25). Oxaliplatin resistance may then be maintained through a separate
mechanism than that of either cisplatin or carboplatin. More research would have to go
into the investigation of the specific resistance against this drug in ovarian cancer. The
mechanism is not known as to how CSS resensitizes cells to cisplatin or carboplatin.
Platinum drugs trigger apoptosis by forming adducts within DNA, something which the
drug triad does not affect. It is possible that simply increasing ER stress and pushing
the cells toward either apoptosis or necrosis overloads the already stressed cell beyond
its capacity to both repair the damaged DNA and cope with the added drug insult
(Figure 26). However, more investigation into the precise mechanism is necessary.
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Figure 26. Abbreviated diagrammatic representation of potential resensitization

mechanism of CSS
The proposed mechanism of action resulting in the observed
responses to drug treatment in this study is represented diagrammatically above.
Platinum drugs form adducts within the structure of nuclear DNA, which may be
repaired enzymatically in platinum resistant cells. CSS leads to apoptosis and necrosis
outright, but also causes ER stress which can lead to apoptosis and necrosis. ER stress
also inhibits the action of repair enzymes which may provide an explanation as to how
CSS restores platinum sensitivity.

88

Conclusion
To conclude, this study demonstrated that sorafenib, celecoxib, and sildenafil
work in combination as a targeted therapy treatment effective in killing ovarian cancer
cells 
in vitro
with a broad spectrum of mutations. The process for such killing is linked
through ER stress, apoptosis, and necrosis. In addition to the ability to kill tumor cells
outright, the drug combination also resensitizes resistant ovarian cancer cells 
in vitro
to
the platinumbased standard of care chemotherapeutics through an as yet unknown
mechanism.
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